317 related articles for article (PubMed ID: 33031789)
1. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Valgimigli M; Cao D; Makkar RR; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Ge J; Neumann FJ; Hermiller J; Picon H; Toelg R; Maksoud A; Chehab BM; Wang LJ; Wang J; Mehran R
Am Heart J; 2021 Jan; 231():147-156. PubMed ID: 33031789
[TBL] [Abstract][Full Text] [Related]
2. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
[TBL] [Abstract][Full Text] [Related]
3. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
Mehran R; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Wang J; Valgimigli M;
JACC Cardiovasc Interv; 2021 Sep; 14(17):1870-1883. PubMed ID: 34503737
[TBL] [Abstract][Full Text] [Related]
4. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
6. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
[TBL] [Abstract][Full Text] [Related]
7. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Mauri L; Kirtane AJ; Windecker S; Yeh RW; Dauerman HL; Price MJ; Christen T; Allocco DJ; Meredith IT; Kereiakes DJ
Am Heart J; 2018 Nov; 205():110-117. PubMed ID: 30218844
[TBL] [Abstract][Full Text] [Related]
9. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.
Cao D; Vranckx P; Valgimigli M; Sartori S; Angiolillo DJ; Bangalore S; Bhatt DL; Feng Y; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Krucoff MW; Kunadian V; Sardella G; Spirito A; Thiele H; Varenne O; Vogel B; Zhou Y; Windecker S; Mehran R
EuroIntervention; 2024 May; 20(10):e630-e642. PubMed ID: 38776146
[TBL] [Abstract][Full Text] [Related]
10. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
[TBL] [Abstract][Full Text] [Related]
11. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
[TBL] [Abstract][Full Text] [Related]
12. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
13. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
Landi A; Wlodarczak A; Tölg R; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G; Valgimigli M;
J Cardiovasc Transl Res; 2023 Oct; 16(5):1135-1143. PubMed ID: 37264295
[TBL] [Abstract][Full Text] [Related]
15. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.
Valgimigli M; Spirito A; Sartori S; Angiolillo DJ; Vranckx P; de la Torre Hernandez JM; Krucoff MW; Bangalore S; Bhatt DL; Campo G; Cao D; Chehab BM; Choi JW; Feng Y; Ge J; Hermiller J; Kunadian V; Lupo S; Makkar RR; Maksoud A; Neumann FJ; Picon H; Saito S; Sardella G; Thiele H; Toelg R; Varenne O; Vogel B; Zhou Y; Windecker S; Mehran R
JACC Cardiovasc Interv; 2023 Oct; 16(20):2498-2510. PubMed ID: 37804290
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.
Natsuaki M; Morimoto T; Watanabe H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Kimura T;
Circ J; 2020 Aug; 84(9):1483-1492. PubMed ID: 32684537
[TBL] [Abstract][Full Text] [Related]
19. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program.
Sardella G; Spirito A; Sartori S; Angiolillo DJ; Vranckx P; Hernandez JMT; Krucoff MW; Bangalore S; Bhatt DL; Campo G; Cao D; Chehab BM; Choi JW; Feng Y; Ge J; Godfrey K; Hermiller J; Kunadian V; Makkar RR; Maksoud A; Neumann FJ; Picon H; Saito S; Thiele H; Toelg R; Varenne O; Vogel B; Zhou Y; Valgimigli M; Windecker S; Mehran R
Am J Cardiol; 2024 Mar; 214():94-104. PubMed ID: 38185438
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Yamaji K; Domei T; Ogita M; Ohya M; Tatsushima S; Suzuki H; Tada T; Ishii M; Nikaido A; Watanabe N; Fujii S; Mori H; Nishikura T; Suematsu N; Hayashi F; Komiyama K; Shigematsu T; Isawa T; Suwa S; Ando K; Kimura T;
JACC Cardiovasc Interv; 2023 Jan; 16(1):19-31. PubMed ID: 36599584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
